aibioLipella's bankruptcy court approves sale of substantially all assets
Tickers LIPO
A bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026.
Key facts
- Company
- Lipella Pharmaceuticals Inc. (OTC: LIPO)
- News type
- Distress
- Primary source
- Lipella Pharmaceuticals Inc. 8-K (2026-07-15)
Lipella Pharmaceuticals Inc. (LIPO) disclosed in a Form 8-K filed July 15, 2026 that the U.S. Bankruptcy Court for the Western District of Pennsylvania approved the sale of substantially all of its assets. The company filed a voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code on March 30, 2026, in Case No. 26-20879-CMB. On May 14, 2026, Lipella entered into an asset purchase agreement with XRAIY, which the filing also refers to as XRAIY LLC, or its designee or designees.
The sale
The court authorized and approved the sale and the asset purchase agreement under section 363 of the Bankruptcy Code by an order dated June 4, 2026, entered at Doc. No. 115. The sale order approves the sale free and clear of all encumbrances. It also authorizes the assumption and assignment of certain executory contracts and unexpired leases. Copies of the sale order and the asset purchase agreement are filed as exhibits to the 8-K. The filing text does not state the purchase price.
Jonathan Kaufman, Chief Executive Officer, signed the filing. The 8-K includes a cautionary note that trading in the common stock during the chapter 11 case is highly speculative and poses substantial risks. The company says trading prices may bear little or no relationship to the actual recovery, if any, that holders of common stock receive in the case.
What the company develops
Lipella describes itself as a clinical-stage biotechnology company that develops new drugs by reformulating the active agents in existing generic drugs. Its annual report filed March 28, 2025 says the strategy is meant to reduce cost, time and risk while creating potential patent protection for its proprietary formulations.
Its lead candidate, LP-10, is a reformulation of tacrolimus designed for topical delivery to the internal surface of the bladder. It uses what the company calls its metastable liposome drug delivery platform, and it is aimed at hemorrhagic cystitis caused by pelvic radiation therapy, also called radiation cystitis. The annual report says no FDA-approved drug currently exists for that condition, and that LP-10 has received FDA orphan drug designation. The first issued U.S. patent covering LP-10 expires July 11, 2035, unless extended for regulatory delay.
The safety and efficacy of LP-10 were evaluated in a 13-subject, open-label, multicenter, dose-escalation phase 2a trial that began on February 15, 2021. The company reported summary results in the first quarter of 2023. That is a small, uncontrolled, early-stage study, and the annual report says Lipella had not commercialized any product and did not expect product revenue for several years.
The second candidate, LP-310, is an oral liposomal formulation of tacrolimus for oral lichen planus, a chronic autoimmune disease of the oral mucosa. Lipella received investigational new drug approval for LP-310 in the third quarter of 2023 and began a phase 2a multicenter dose-escalation study in 2024. The annual report says eight participants in the first cohort received a dose of 0.25 mg, with no product-related serious adverse events reported, a very small safety sample.
Financial position
The XBRL financial data, drawn from the company's filings, shows revenue of $536,357 for the fiscal year ended December 31, 2024, compared with $449,617 for 2023. Research and development expense was $3.6 million for 2024, compared with $3.0 million for 2023. The company reported a net income (loss) of negative $5.0 million for 2024, compared with negative $4.6 million for 2023, and cash from operations of negative $4.0 million for 2024, compared with negative $3.2 million for 2023.
The same data shows cash and cash equivalents of $1.9 million at September 30, 2025, from its quarterly report.
What the filing leaves open
The company was in chapter 11 with $1.9 million of cash at September 30, 2025, and a net loss of negative $5.0 million for 2024, so the sale is a restructuring outcome, not a growth deal. The 8-K does not give a closing date for the sale. It does not say how the sale proceeds will be distributed or what the sale means for the common stock. The sale order and the asset purchase agreement are the documents that set the terms, and both are filed with the 8-K.